Table 2 Characteristics and antibody levels and prevalence to antigens in villagers from Dielmo and Ndiop 200
From: Practical example of multiple antibody screening for evaluation of malaria control strategies
| Â | Dielmo | Ndiop | ||||
|---|---|---|---|---|---|---|
2002 | 2013 | %Change5 | 2002 | 2013 | %Change5 | |
No1 | 75 | Â | 86 | Â | Â | |
M/F | 26/49 | Â | 29/57 | Â | ||
HbAA/AS/C1 | 67/7/1 | Â | 74/8/4 | Â | ||
Age of Individuals | 30.3 [3.8–80] | 41.5 [14.9–91.5] |  | 26.8 [3.4–68.1] | 37.8 [14.4–79.1] |  |
No < 15y2 | 20 |  | 28 |  | ||
IgG SE < 15y3 | 4.9 [1.2–9] | 3.6 [1–8.2] | − 27% | 3.6 [1.0–6.7] | 2.5 [1.0–5.4] | –31% |
IgG SE > 15y | 6.1 [1.3–11.1] | 4.8 [1.2–11.4] | − 21% | 4.7 [1.0–7.8] | 4.1 [1.0–7.1] | –12% |
IgG SE all individuals | 5.8 [1.2–11.1] | 4.5 [1–11.4] | − 22% | 4.3 [1.0–7.8] | 3.6 [1.0–7.1] | –17% |
Prev. SE < 15y | 85% | 75% | − 12% | 82% | 54% | –25% |
Prev. SE > 15y | 96% | 93% | − 4% | 84% | 84% | 0% |
IgG LSA1 < 15y4 | 1.5 [0.04–9.1] | 0.4 [0.02–1.7] | − 72% | 0.7 [0.02–7.4] | 0.5 [0.02–4.1] | –24% |
IgG LSA1 > 15y | 1.8 [0.04–12.6] | 1.1 [0.02–6.0] | − 42% | 2.3 [0.03–12.6] | 1.8 [0.02–16.3] | –18% |
IgG LSA1 all individuals | 1.8 [0.04–12.6] | 0.9 [0.02–6.0] | − 49% | 1.8 [0.03–12.6] | 1.5 [0.02–16.3] | –19% |
Prev. LSA1 < 15y | 80% | 75% | − 6% | 61% | 54% | –12% |
Prev. LSA1 > 15y | 85% | 73% | − 15% | 86% | 78% | –10% |
IgG MSP1 < 15y4 | 0.9 [0.09–3.2] | 0.4 [0.02–2.0] | − 58% | 1.6 [0.02–12.9] | 1.2 [0.03–12.1] | –26% |
IgG MSP1 > 15y | 4.3 [0.02–10.7] | 2.9 [0.04–12.0] | − 33% | 4.1 [0.2–16.2] | 3.3 [0.05–16.6] | –10% |
IgG MSP1 all individuals | 3.4 [0.02–10.7] | 2.9 [0.02–12.0] | − 35% | 3.3 [0.02–16.2] | 2.6 [0.03–16.6] | –21% |
Prev. MSP1 < 15y | 60% | 30% | − 50% | 61% | 46% | –24% |
Prev. MSP1 > 15y | 85% | 91% | + 3% | 88% | 79% | –10% |